SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
SEC Accession No. 0001104659-22-023143
Filing Date
2022-02-14
Accepted
2022-02-14 17:07:16
Documents
2
Group Members
JEREMY C. GREEN

Document Format Files

Seq Description Document Type Size
1 SC 13G/A tm226094d30_sc13ga.htm SC 13G/A 72201
2 EXHIBIT 99.1 tm226094d30_ex99-1.htm EX-99.1 5229
  Complete submission text file 0001104659-22-023143.txt   79217
Mailing Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102
Business Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102 206-732-2133
Neoleukin Therapeutics, Inc. (Subject) CIK: 0001404644 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-88050 | Film No.: 22634501
SIC: 2834 Pharmaceutical Preparations

Mailing Address ONE LETTERMAN DRIVE BUILDING D, SUITE D3-300 SAN FRANCISCO CA 94129
Business Address ONE LETTERMAN DRIVE BUILDING D, SUITE D3-300 SAN FRANCISCO CA 94129 415-489-9980
Redmile Group, LLC (Filed by) CIK: 0001425738 (see all company filings)

IRS No.: 208592298 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A